PACB News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PA

Mkt Cap

$539.3M

Volume

10.12M

Next Earnings

November 4th

Loading chart

PA

PACBPacific Biosciences of California, Inc.

PACB

Pay with—

Available Balance0.00

PA

Mkt Cap

$537.7M

Volume

10.12M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for InvestorsPacific Biosciences of California (PACB) closed at $1.99, down 2.93%, underperforming the S&P 500's 1.11% loss. Despite a 52.99% monthly gain, the company faces headwinds with expected EPS of -$0.13 (down 8.33% YoY) and revenue of $37.86 million (down 1.51% YoY). The stock holds a Zacks Rank #3 (Hold) rating with steady consensus estimates.Zacks Investment Research · Oct 14, 2026

PacBio Teams With TychoBio to Advance AI-Driven RNA TherapeuticsPacific Biosciences announced a collaboration with TychoBio to generate full-length RNA sequencing data for training AI models designed to develop RNA therapies for rare diseases. TychoBio will analyze over 10,000 samples using PacBio's HiFi and Kinnex sequencing technologies to build datasets linking RNA therapy designs to their effects, with initial focus on steric blocking antisense oligonucleotides. The partnership strengthens PacBio's presence in rare disease research and could drive demand for its sequencing platforms.Zacks Investment Research · Oct 13, 2026

Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market TodayPacific Biosciences of California (PACB) fell 15.44% on October 8, 2026, significantly underperforming the S&P 500's 0.47% decline. Despite a strong 110.85% gain over the past month, the genetic analysis technology company faces headwinds with projected EPS of -$0.13 (down 8.33% YoY) and revenue expected at $37.86 million (down 1.51% YoY). The stock holds a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Oct 8, 2026

Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGRThe global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.GlobeNewswire Inc. · Oct 5, 2026

Pacific Biosciences of California (PACB) Rises Higher Than Market: Key FactsPacific Biosciences of California (PACB) stock rose 1.2% to $2.54, outperforming the S&P 500's 0.73% gain. Despite a 93.08% monthly surge, the company faces headwinds with projected EPS of -$0.13 (down 8.33% YoY) and revenue of $37.86 million (down 1.51% YoY). PACB holds a Zacks Rank of #4 (Sell) with unchanged consensus estimates over the past 30 days.Zacks Investment Research · Oct 2, 2026

Why Pacific Biosciences of California (PACB) Outpaced the Stock Market TodayPacific Biosciences of California (PACB) gained 2.99% on September 17, 2026, outperforming the S&P 500's 1.14% gain. The stock has climbed 5.51% over the past month. However, the company faces headwinds with projected earnings decline of 8.33% year-over-year and a Zacks Rank of #4 (Sell), indicating negative analyst sentiment despite recent price momentum.Zacks Investment Research · Sep 17, 2026

Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should KnowPacific Biosciences of California (PACB) declined 1.55% to $1.27, underperforming the S&P 500's 0.59% loss. Despite a 16.22% gain over the past month, the company faces headwinds with projected EPS of -$0.13 (down 8.33% YoY) and revenue of $37.86 million (down 1.51% YoY). PACB holds a Zacks Rank of #4 (Sell) with stagnant EPS projections over the past 30 days.Zacks Investment Research · Sep 10, 2026

AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision MedicineArtificial intelligence is fundamentally restructuring bioinformatics, compressing drug discovery timelines and attracting billions in venture capital. AI tools like AlphaFold and generative biology platforms are delivering measurable ROI, with companies achieving 99% cost reductions in drug discovery. North America leads adoption, supported by federal programs and substantial R&D investments from established life sciences players.GlobeNewswire Inc. · Aug 6, 2026

Global Metagenomics Sequencing Market to Register Stunning Growth at a CAGR of ~13% by 2034 | DelveInsightThe global metagenomics sequencing market is projected to grow from USD 2.5 billion in 2025 to USD 7.5 billion by 2034, driven by declining NGS costs, rising infectious disease burden, microbiome research expansion, and clinical diagnostic adoption. North America leads with 41% market share, while Asia-Pacific emerges as a major growth engine.GlobeNewswire Inc. · Apr 29, 2026

Omics-Based Clinical Trials Research Report 2026: $47.78 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe omics-based clinical trials market is experiencing robust growth, expanding from $31.71 billion in 2025 to $34.49 billion in 2026 with an 8.8% CAGR, and projected to reach $47.78 billion by 2030. Growth is driven by increasing demand for personalized medicine, genomics advancements, AI-enabled patient recruitment, and biomarker-driven trial designs. North America leads the market while Asia-Pacific shows rapid expansion potential.GlobeNewswire Inc. · Apr 24, 2026

to start trading

PA

PACBPacific Biosciences of California, Inc.

PACB

Pay with—

Available Balance0.00

Your PositionYou don't own any PACB yet.

Related Tickers

Earnings